Reuters logo
BRIEF-Shire receives European approval for label extension of firazyr for symptomatic treatment
October 26, 2017 / 6:16 AM / in a month

BRIEF-Shire receives European approval for label extension of firazyr for symptomatic treatment

Oct 26 (Reuters) - SHIRE PLC:

* SHIRE RECEIVES EUROPEAN APPROVAL FOR LABEL EXTENSION OF FIRAZYR (ICATIBANT INJECTION) FOR THE SYMPTOMATIC TREATMENT OF ACUTE HAE ATTACKS IN PAEDIATRIC PATIENTS

* FIRAZYR WILL BE AVAILABLE FOR USE IN PAEDIATRIC PATIENTS IN EUROPE BEGINNING IN Q4​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below